Tex. Health & Safety Code § 51.0004 · Chapter 51. CANCER CLINICAL TRIAL PARTICIPATION PROGRAM
REIMBURSEMENT REQUIREMENTS; NOTICE.
Text — Current through the 89th 2nd Called Legislative Session, 2025
(a) A reimbursement under the program must:
(1) be reviewed and approved by the institutional review board associated with the cancer clinical trial for which the reimbursement is provided; and
(2) comply with applicable federal and state laws.
(b) The independent, third-party organization operating the program is not required to obtain approval from an institutional review board on the financial eligibility of a subject who is medically eligible for the program.
(c) The independent, third-party organization operating the program shall provide written notice to a subject on:
(1) the nature and availability of the ancillary financial support under the program; and
(2) the program's general guidelines on financial eligibility.
Notes and commentary — not statutory text
History
Added by Acts 2019, 86th Leg., R.S., Ch. 1157 (H.B. 3147), Sec. 2, eff. September 1, 2019.
Redesignated by Acts 2021, 87th Leg., R.S., Ch. 915 (H.B. 3607), Sec. 21.001(53), eff. September 1, 2021.
Source of truth
- Edition
- Current through the 89th 2nd Called Legislative Session, 2025
- Official file
- https://statutes.capitol.texas.gov/Docs/HS/htm/HS.51.htm
- Text hash
- sha256 47948b67a6fdba8ddd0a42c423d13ea882fc3fb886ca71204df95fd9aad4c11f
- Composed by
- compose_tx.py 2026-10-05: the Legislative Council's chapter files read in document order; verify_tx.py's independent reading (lxml DOM walk) agrees character for character
Procedural information only. Not legal advice and not a substitute for the advice of an attorney. Confirm the current text with the official publisher before relying on it.